KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAssetsBuildingsCash & Current InvestmentsCash & EquivalentsCommon EquityConstruction in ProgressCurrent AssetsCurrent Deferred RevenueGoodwillGoodwill & IntangiblesIntangiblesInventoryLand & ImprovementsLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsMinority InterestNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNon-Current Deferred Tax LiabilityOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Bristol Myers Squibb (BMY) Work In Process (2010 - 2013)

Bristol Myers Squibb (BMY) reported Work In Process of $884.0 million for Q1 2013, up 22.61% year-over-year from $721.0 million in Q1 2012, and up 8.6% on a QoQ basis from $814.0 million in Q4 2012.

Bristol Myers Squibb (BMY) has 4 years of Work In Process data on file, last reported at $884.0 million in Q1 2013.

  • Quarterly Work In Process rose 22.61% year-over-year to $884.0 million in Q1 2013, while the trailing twelve-month figure through Mar 2013 was $884.0 million (up 22.61% YoY) and the FY2012 annual result came in at $814.0 million, up 26.01% from the prior year.
  • Work In Process climbed to $884.0 million in Q1 2013 per BMY's latest filing, from $814.0 million in the prior quarter.
  • Across five years, Work In Process topped out at $884.0 million in Q1 2013 and bottomed at $608.0 million in Q4 2010.
  • The 4-year median for Work In Process is $715.0 million (2011), against an average of $739.3 million.
  • Peak annual rise in Work In Process reached 26.01% in 2012, while the deepest fall reached 4.49% in 2012.
  • Tracing BMY's Work In Process over 4 years: stood at $608.0 million in 2010, then increased by 6.25% to $646.0 million in 2011, then gained by 26.01% to $814.0 million in 2012, then rose by 8.6% to $884.0 million in 2013.
  • Per Business Quant, the three latest BMY Work In Process figures stand at $884.0 million (Q1 2013), $814.0 million (Q4 2012), and $868.0 million (Q3 2012).

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Novartis Ag 107,124,802.25 Bn 107,124,802.25 Bn -
2 Eli Lilly 969.00 Bn 963.72 Bn 16.22 Bn
3 Johnson & Johnson 539.46 Bn 517.41 Bn 15.96 Bn
4 AbbVie 376.92 Bn 367.57 Bn 10.78 Bn
5 Merck 285.00 Bn 279.35 Bn 12.09 Bn
6 Amgen 177.58 Bn 165.55 Bn 5.87 Bn
7 Gilead Sciences 163.22 Bn 155.50 Bn 5.52 Bn
8 Pfizer 145.86 Bn 133.09 Bn -1.21 Bn
9 Bristol Myers Squibb 111.90 Bn 101.44 Bn 8.07 Bn
10 Gsk 88.34 Bn 83.66 Bn -

Historic Data

Download Data 🔒
DateValue
Mar 31, 2013 884.00 Mn
Dec 31, 2012 814.00 Mn
Sep 30, 2012 868.00 Mn
Jun 30, 2012 755.00 Mn
Mar 31, 2012 721.00 Mn
Dec 31, 2011 646.00 Mn
Sep 30, 2011 709.00 Mn
Jun 30, 2011 698.00 Mn
Mar 31, 2011 690.00 Mn
Dec 31, 2010 608.00 Mn